Community acquired pneumonia incidence among children less than 5 years of age in Concordia, Argentina: vaccination impact

Objective. To measure the effectiveness of pneumococcal conjugated vaccine (PCV13) against Community Acquired Pneumonia (CAP) and invasive pneumococcal disease, 2 years after the vaccine (2+1) was included into the National Immunization Program of Argentina, and to describe variables associated with...

Full description

Bibliographic Details
Main Authors: Raúl O. Ruvinsky, Analía Rearte, Judit Kupervaser, Fernando Gentile, Adriana Haidar, Maria E. Cafure, Maria Elisa Tito, Federico Avaro, Cristina Cortiana, Hugo Cozzani, Omar Véliz, Sofia Fossati, Mabel Regueira, Carla Vizzotti
Format: Article
Language:English
Published: Pan American Health Organization 2018-11-01
Series:Revista Panamericana de Salud Pública
Subjects:
Online Access:http://iris.paho.org/xmlui/handle/123456789/49588
id doaj-3eeedd1bdc4a4b9b972a3b1f4d49dddf
record_format Article
spelling doaj-3eeedd1bdc4a4b9b972a3b1f4d49dddf2020-11-24T21:51:18ZengPan American Health OrganizationRevista Panamericana de Salud Pública1020-49891680-53482018-11-01421810.26633/RPSP.2018.167e167Community acquired pneumonia incidence among children less than 5 years of age in Concordia, Argentina: vaccination impactRaúl O. Ruvinsky0Analía Rearte1Judit Kupervaser2Fernando Gentile3Adriana Haidar4Maria E. Cafure5Maria Elisa Tito6Federico Avaro7Cristina Cortiana8Hugo Cozzani9Omar Véliz10Sofia Fossati11Mabel Regueira12Carla Vizzotti13Dirección de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, Buenos Aires, ArgentinaDirección de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, Buenos Aires, ArgentinaHospital Delicia Concepción Masvernat, Concordia, Entre Ríos, ArgentinaHospital de Niños Ricardo Gutiérrez, Buenos Aires, ArgentinaHospital Delicia Concepción Masvernat, Concordia, Entre Ríos, ArgentinaCentro Provincial de Salud Constitución, Concordia, Entre Ríos, ArgentinaHospital Delicia Concepción Masvernat, Concordia, Entre Ríos, ArgentinaHospital Felipe Heras, Concordia, Entre Ríos, ArgentinaHospital Ramón Carrillo, Concordia, Entre Ríos, ArgentinaHospital de Niños Ricardo Gutiérrez, Buenos Aires, ArgentinaBacteriología Clínica, Instituto Nacional de Enfermedades Infecciosas, Administración Nacional de Laboratorios e Institutos de Salud “Dr. Carlos Malbrán,” Buenos Aires, ArgentinaBacteriología Clínica, Instituto Nacional de Enfermedades Infecciosas, Administración Nacional de Laboratorios e Institutos de Salud “Dr. Carlos Malbrán,” Buenos Aires, ArgentinaBacteriología Clínica, Instituto Nacional de Enfermedades Infecciosas, Administración Nacional de Laboratorios e Institutos de Salud “Dr. Carlos Malbrán,” Buenos Aires, ArgentinaDirección de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, Buenos Aires, ArgentinaObjective. To measure the effectiveness of pneumococcal conjugated vaccine (PCV13) against Community Acquired Pneumonia (CAP) and invasive pneumococcal disease, 2 years after the vaccine (2+1) was included into the National Immunization Program of Argentina, and to describe variables associated with bacterial pneumonia and hospitalization. Methods. This was a prospective, population-based surveillance study of CAP incidence (ambulatory and hospitalized) among children less than 5 years of age in the Department of Concordia (Entre Rios, Argentina) from April 2014 – March 2016. The diagnosis of probable bacterial pneumonia (PBP) was determined following the standardized WHO protocol. Incidence during the post-vaccine introduction period was compared with the results from a previous study that used similar methodology for the pre-PCV13 introduction period from 2002 – 2005. Results. During the study period, 330 patients had a clinical diagnosis of CAP, of which 92 were PBP (6 with pleural effusion). S. pneumoniae was not isolated from any sample. No factors associated with PBP were found in multivariable analysis. The decrease in PBP and pleural effusion was significant in relation to the previous study: 63% (P < 0.0001) and 80.9% (P < 0.003), respectively. PCV13 uptake was 97.3% for the 1st dose and 84.8% for the booster dose. Conclusions. PCV13 was effective to reduce incidence of consolidated pneumonia and pleural effusion, among children less than 5 years of age in Concordia, Argentina. Vaccination is a very effective public health strategy for reducing vaccine preventable diseases, with impact on burden of disease and hospitalization.http://iris.paho.org/xmlui/handle/123456789/49588Pneumonia, pneumococcalStreptococcus pneumoniaepneumococcal vaccinesimmunization programsArgentina
collection DOAJ
language English
format Article
sources DOAJ
author Raúl O. Ruvinsky
Analía Rearte
Judit Kupervaser
Fernando Gentile
Adriana Haidar
Maria E. Cafure
Maria Elisa Tito
Federico Avaro
Cristina Cortiana
Hugo Cozzani
Omar Véliz
Sofia Fossati
Mabel Regueira
Carla Vizzotti
spellingShingle Raúl O. Ruvinsky
Analía Rearte
Judit Kupervaser
Fernando Gentile
Adriana Haidar
Maria E. Cafure
Maria Elisa Tito
Federico Avaro
Cristina Cortiana
Hugo Cozzani
Omar Véliz
Sofia Fossati
Mabel Regueira
Carla Vizzotti
Community acquired pneumonia incidence among children less than 5 years of age in Concordia, Argentina: vaccination impact
Revista Panamericana de Salud Pública
Pneumonia, pneumococcal
Streptococcus pneumoniae
pneumococcal vaccines
immunization programs
Argentina
author_facet Raúl O. Ruvinsky
Analía Rearte
Judit Kupervaser
Fernando Gentile
Adriana Haidar
Maria E. Cafure
Maria Elisa Tito
Federico Avaro
Cristina Cortiana
Hugo Cozzani
Omar Véliz
Sofia Fossati
Mabel Regueira
Carla Vizzotti
author_sort Raúl O. Ruvinsky
title Community acquired pneumonia incidence among children less than 5 years of age in Concordia, Argentina: vaccination impact
title_short Community acquired pneumonia incidence among children less than 5 years of age in Concordia, Argentina: vaccination impact
title_full Community acquired pneumonia incidence among children less than 5 years of age in Concordia, Argentina: vaccination impact
title_fullStr Community acquired pneumonia incidence among children less than 5 years of age in Concordia, Argentina: vaccination impact
title_full_unstemmed Community acquired pneumonia incidence among children less than 5 years of age in Concordia, Argentina: vaccination impact
title_sort community acquired pneumonia incidence among children less than 5 years of age in concordia, argentina: vaccination impact
publisher Pan American Health Organization
series Revista Panamericana de Salud Pública
issn 1020-4989
1680-5348
publishDate 2018-11-01
description Objective. To measure the effectiveness of pneumococcal conjugated vaccine (PCV13) against Community Acquired Pneumonia (CAP) and invasive pneumococcal disease, 2 years after the vaccine (2+1) was included into the National Immunization Program of Argentina, and to describe variables associated with bacterial pneumonia and hospitalization. Methods. This was a prospective, population-based surveillance study of CAP incidence (ambulatory and hospitalized) among children less than 5 years of age in the Department of Concordia (Entre Rios, Argentina) from April 2014 – March 2016. The diagnosis of probable bacterial pneumonia (PBP) was determined following the standardized WHO protocol. Incidence during the post-vaccine introduction period was compared with the results from a previous study that used similar methodology for the pre-PCV13 introduction period from 2002 – 2005. Results. During the study period, 330 patients had a clinical diagnosis of CAP, of which 92 were PBP (6 with pleural effusion). S. pneumoniae was not isolated from any sample. No factors associated with PBP were found in multivariable analysis. The decrease in PBP and pleural effusion was significant in relation to the previous study: 63% (P < 0.0001) and 80.9% (P < 0.003), respectively. PCV13 uptake was 97.3% for the 1st dose and 84.8% for the booster dose. Conclusions. PCV13 was effective to reduce incidence of consolidated pneumonia and pleural effusion, among children less than 5 years of age in Concordia, Argentina. Vaccination is a very effective public health strategy for reducing vaccine preventable diseases, with impact on burden of disease and hospitalization.
topic Pneumonia, pneumococcal
Streptococcus pneumoniae
pneumococcal vaccines
immunization programs
Argentina
url http://iris.paho.org/xmlui/handle/123456789/49588
work_keys_str_mv AT rauloruvinsky communityacquiredpneumoniaincidenceamongchildrenlessthan5yearsofageinconcordiaargentinavaccinationimpact
AT analiarearte communityacquiredpneumoniaincidenceamongchildrenlessthan5yearsofageinconcordiaargentinavaccinationimpact
AT juditkupervaser communityacquiredpneumoniaincidenceamongchildrenlessthan5yearsofageinconcordiaargentinavaccinationimpact
AT fernandogentile communityacquiredpneumoniaincidenceamongchildrenlessthan5yearsofageinconcordiaargentinavaccinationimpact
AT adrianahaidar communityacquiredpneumoniaincidenceamongchildrenlessthan5yearsofageinconcordiaargentinavaccinationimpact
AT mariaecafure communityacquiredpneumoniaincidenceamongchildrenlessthan5yearsofageinconcordiaargentinavaccinationimpact
AT mariaelisatito communityacquiredpneumoniaincidenceamongchildrenlessthan5yearsofageinconcordiaargentinavaccinationimpact
AT federicoavaro communityacquiredpneumoniaincidenceamongchildrenlessthan5yearsofageinconcordiaargentinavaccinationimpact
AT cristinacortiana communityacquiredpneumoniaincidenceamongchildrenlessthan5yearsofageinconcordiaargentinavaccinationimpact
AT hugocozzani communityacquiredpneumoniaincidenceamongchildrenlessthan5yearsofageinconcordiaargentinavaccinationimpact
AT omarveliz communityacquiredpneumoniaincidenceamongchildrenlessthan5yearsofageinconcordiaargentinavaccinationimpact
AT sofiafossati communityacquiredpneumoniaincidenceamongchildrenlessthan5yearsofageinconcordiaargentinavaccinationimpact
AT mabelregueira communityacquiredpneumoniaincidenceamongchildrenlessthan5yearsofageinconcordiaargentinavaccinationimpact
AT carlavizzotti communityacquiredpneumoniaincidenceamongchildrenlessthan5yearsofageinconcordiaargentinavaccinationimpact
_version_ 1725879266416001024